Plasma for fractionation: Safety and quality issues

Haemophilia

Volumn 10, Issue 4, 2004, Pages 334-340

  Farrugia, Albert ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

Plasma; Products; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; IMMUNOGLOBULIN; PLASMA SUBSTITUTE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APHERESIS; BLOOD SAMPLING; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG STORAGE; FRACTIONATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NUCLEIC ACID ANALYSIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RECIPIENT; REVIEW; SCREENING TEST; VIRUS; VIRUS INFECTION;

EID: 4043103391     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00911.x     Document Type: Review

References (24)

1. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion 1991; 31: 4-11.
2. Kreil TR. Prion Partitioning during Plasma Fractionation: A Consolidated View. Presented to the Joint meeting of the FDA's Transmissible Spongiform Encephalopathy Advisory Committee and Blood Products Advisory Committee, 17 January 2002. On http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3834t2_01.pdf. Accessed on 12 April 2004.
3. Food and Drug Administration. Guidance for Industry. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. 2001. Available at http://www.fda.gov/cber/gdlns/cjdvcjd.pdf. Accessed on 12 April 2004.
4. Ragni MV, Winkelstein A, Kingsley L, Spreo JA, Lewis JH. 1986 update of HIV seroprevalenence, serocon-version, AIDS incidence and immunologic correlates with HIV infection in patients with hemophilia A and B. Blood 1987; 70: 786-90.
5. Busch MP. Viral risks from blood transfusions and patterns of viraemia relevant to efficacy of pathogen reduction procedures. In: Proceedings of an FDA Workshop on Pathogen Reduction Technology. 2002. Available on http://www.fda.gov/cber/minutes/pathtrans080702.htm. Accessed on 12 April 2004.
6. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophillic patients infected between 1961 and 1985. Gut 2000; 6: 845-51.
7. Winkelman L, Owen NE, Evans DR et al. Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 1989; 57: 97-103.
8. Smith JK, Winkelman L, Feldman PA. Interim results of surveillance for NANBH in patients receiving heated concentrates produced in England. Dev Biol Stand 1987; 67: 323-5.
9. Winkelman L, Feldman PA, Evans DR. Severe heat treatment of lyophilised coagulation factors. Curr Stud Hematol Blood Transfus 1989; 56: 55-69.
10. Centers for Disease Control. Blood safety monitoring among persons with bleeding disorders - United States, May 1998-June 2002. JAMA 2003; 289: 541-3.
11. Bresee JS, Mast EE, Coleman PJ et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 1996; 276: 1563-7.
12. Yu MW, Mason BL, Guo ZP et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995; 345: 1173-4.
13. Farrugia A, Walker E. Hepatitis C virus transmission by intravenous immunoglobulin. Lancet 1995; 346: 373.
14. Health Council of the Netherlands. Blood Products and Parvovirus B19. On http://www.gr.nl/pdf.php?ID=433. Accessed on 12 April 2004.
15. Plasma Protein Therapies Association. Voluntary Industry Standards. On http://www.pptaglobal.org/en/qualitysafety-qseal.cfm. Accessed on 12 April 2004.
16. Callaghan E. Standards for Recovered Plasma. Presented to the Blood, Products Advisory Committee of the FDA June 2002 and June 2003. Available on http://www.fda.gov/OHRMS/DOCKETS/ac/02/briefing/ Recovered%20plasma-BPAC%206-02.doc and http://www.fda.gov/ohrms/dockets/ ac/03/briefing/3961b1_Callaghanrecovered%20plasma.ppt.Accessed on 12 April 2004.
17. European Medicines Evaluation Agency. Contribution to part 2.3 of the Structure of the Dossier for Applications for Marketing Authorisation - Control of Starting Materials for the Production of Plasma-derived Medicinal Products (draft), 2001. On http://www.emea.eu.int/pdfs/human/bwp/205301en.pdf. Accessed on 12 April 2004.
18. Waytes AT, Igel H, Zerlauth G et al. A safer plasma supply from remunerated donors - 'The Immuno/Community Bio-Resources Experiment'. Dev Biol 2000; 102: 37-52.
19. Farrugia A. Guide for the Assessment of Clotting Factor Concentrates for the Treatment of Hemophilia. On http://www.wfh.org/Content_Documents/Other_Publications/ Reg_Guide_Eng.pdf. Accessed on 12 April 2004.
20. Manucci PM, Tuddenham EGD. The haemophilias - from royal genes to gene therapy. NEJM 2001; 344: 1773-9.
21. European Commission. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 Setting Standards of Quality and Safety for the Collection, Testing, Processing, Storage and Distribution of Human Blood and Blood Components and Amending Directive 2001/83/EC. On http://pharmacos.eudra.org/F2/eudralex/vol-1/new-v1/ Dir2OO2-98_EN.pdf. Accessed on 12 April 2004.
22. Hyland C. NAT Screening for Hepatitis C and HIV-1 Viral Genomes - NAT two years on. Presented to the 36th Annual Meeting of the Australia and New Zealand Society for Blood Transfusion, 2002.
23. Seed CR, Cheng A, Ismay SL et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002; 42: 1365-72.
24. Lelie PN, van Drimmelen HAJ, Cuypers HTM et al. Sensitivity of HCV and HIV RNA blood screening assays. Transfusion 2002; 42: 527-36.